Evidence map›Paper›PMID 27884155›Full record

ArticleLipids in health and disease2016

Long chain polyunsaturated fatty acids (LCPUFAs) and nordihydroguaiaretic acid (NDGA) modulate metabolic and inflammatory markers in a spontaneous type 2 diabetes mellitus model (Stillman Salgado rats).

Alejandro Dain, Gaston Repossi, Gustavo T Diaz-Gerevini, Jairam Vanamala, Undurti N Das, Aldo R Eynard

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Alejandro DainBiología Celular, Histología y Embriología, Facultad de Ciencias Medicas, INICSA (CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina.
Gaston RepossiBiología Celular, Histología y Embriología, Facultad de Ciencias Medicas, INICSA (CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina.
Gustavo T Diaz-GereviniBiología Celular, Histología y Embriología, Facultad de Ciencias Medicas, INICSA (CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina.
Jairam VanamalaDepartment of Food Science, Penn State University, 326 Food Science Building, University Park, PA, 16802, USA.
Undurti N DasUND Life Sciences, 2020 S 360th St, # K-202, Federal Way, WA, 98003, USA. Undurti@hotmail.com.
Aldo R EynardBiología Celular, Histología y Embriología, Facultad de Ciencias Medicas, INICSA (CONICET-Universidad Nacional de Córdoba), Córdoba, Argentina. aeynard@gmail.com.
Centro Científico Tecnológico - Córdoba · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARInstituto de Investigaciones en Ciencias de la Salud · ARPennsylvania State University · USUniversidad Nacional de Córdoba · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus (DM) is a complex disease with alterations in metabolic and inflammatory markers. Stillman Salgado rats (eSS) spontaneously develop type 2 DM by middle age showing progressive impairment of glucose tolerance with hyperglycemia, hypertriglyceridemia and hyperinsulinemia. We analyzed the effects of supplementation of ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) with or without nordihydroguaiaretic acid (NDGA) added, an antioxidant and lipoxygenase inhibitor, on metabolic and inflammatory parameters in eSS rats to evaluate whether they can delay development and/or prevent progression of DM.

methodsAfter weaning, eSS rats received, intraperitoneally, once a month ω-3 (EPA 35% and DHA 40%-6.25 mg/Kg) or ω-6 (90% arachidonic acid- 6. 25 mg/Kg) for twelve months. Two additional groups of rats received 1.9 mg/kg NDGA added to ω-3 and ω-6 fatty acids. Blood samples were collected at day 40, and at the end of the 6th month and 12th month of age to determine plasma triglycerides (TGs), total plasma fatty acids (FA), A1C hemoglobin (HbA1C), C-reactive protein (CRP), gamma glutamyl transpeptidase (GGT), lipo and hydro peroxides, nitrites and IL-6 (in plasma and liver, kidney, and pancreas) and underwent oral glucose tolerance test (OGTT) as well. Wistar and eSS rats that received saline solution were used as controls.

resultsPlasma lipids profile, TG, fasting and post-prandial blood glucose levels, and glycosylated HbA1C showed significant improvements in ω-3 and ω-3 + NDGA treated animals compared to eSS control group. ω-3 and ω-3 + NDGA groups showed an inverse correlation with fasting blood glucose and showed lower plasma levels of GGT, TG, and CRP. eSS rats treated with ω-3 LCPUFAs showed reduced level of inflammatory and oxidative indices in plasma and liver, kidney and pancreas tissues in comparison with eSS control (non-treated) and ω-6 treated groups.

conclusionseSS rats are a useful model to study type 2 DM pathophysiology and related inflammatory indices. ω-3 + NDGA supplementation, at the doses tested, ameliorated inflammatory, metabolic and oxidative stress markers studied.

Indexed as

Dietary SupplementsAnimalsArachidonic AcidBiomarkersC-Reactive ProteinDiabetes Mellitus, Type 2Disease Models, AnimalFatty Acids, Omega-3gamma-GlutamyltransferaseGlycated HemoglobinInflammationInterleukin-6MaleMasoprocolRatsRats, WistarArachidonic AcidBiomarkersC-Reactive ProteinFatty Acids, Omega-3gamma-GlutamyltransferaseGlycated HemoglobinInterleukin-6MasoprocolTriglyceridesChronic inflammationeSS rats (Stillman Salgado rats)Nordihydroguaiaretic acidOxidation processPlasma triglyceridesPUFAsType 2 diabetes

Identifiers

PMID27884155
PMCPMC5123226
OpenAlexW2551795439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.